Specification of Drug Substances and Products: Development and Validation of Analytical Methods

Riley, Christopher M. (Editor)/ Rosanske, Thomas W. (Editor)/ Reid, George L. (Editor)

ISBN 10: 0081028245 / ISBN 13: 9780081028247

Editore: Elsevier Science Ltd, 2020

Riguardo questo articolo

2nd reprint edition. 712 pages. 9.25x7.50x1.38 inches. In Stock.

Codice articolo __0081028245

Dati bibliografici

• Titolo: Specification of Drug Substances and Products: Development and Validation of Analytical Methods
• Editore: Elsevier Science Ltd
• Data di pubblicazione: 2020
• Lingua: Inglese
• ISBN 10: 0081028245
• ISBN 13: 9780081028247
• Rilegatura: Paperback
• Edizione: seconda edizione
• Condizione: Brand New

Descrizione articolo

Riassunto

Specification of Drug Substances and Products: Development and Validation of Analytical Methods, Second Edition, presents a comprehensive and critical analysis of the requirements and approaches to setting specifications for new pharmaceutical products, with an emphasis on phase-appropriate development, validation of analytical methods, and their application in practice. This thoroughly revised second edition covers topics not covered or not substantially covered in the first edition, including method development and validation in the clinical phase, method transfer, process analytical technology, analytical life cycle management, special challenges with generic drugs, genotoxic impurities, topical products, nasal sprays and inhalation products, and biotechnology products.

The book's authors have been carefully selected as former members of the ICH Expert Working Groups charged with developing the ICH guidelines, and/or subject-matter experts in the industry, academia and in government laboratories.

Informazioni sugli autori

Dr. Christopher Riley is the President of Riley and Rabel Consulting Services. He received a bachelor’s degree in Pharmacy (1977) and PhD degree in Pharmaceutical Chemistry (1980) from the University of Bath, UK. He taught Pharmaceutical Chemistry, at the Universities of Florida (1983-6) and the University of Kansas (1986-94), and was a Vice President at DuPont Merck (1994-2001) and ALZA (a division of J&J) (2001-7). He has coauthored more than 140 book chapters and papers in peer-reviewed journals, as well as 5 books. He has extensive experience in CMC regulatory affairs and the development of all types of dosage forms.

Former Director of Business Development at Acceleration Laboratory Services, Incorporated. He has previously held scientific and senior management positions at The Upjohn Company, Marion Laboratories, Marion Merrell Dow, Hoechst Marion Roussel, Quintiles, Eli Lilly, Beckloff Associates, and PPD. He currently serves on a Small Molecule USP Expert Committee.